10-Q · May 1, 2026
Thermo Fisher reported a strong Q1 2026 with revenue of $11,005 million, marking a 6% year-over-year growth, and adjusted EPS of $5.44, an 11% increase from the previous year. The Laboratory Products and Biopharma…
Earnings analysis · 10-Q
TMO earnings analysis
Filed October 30, 2026 · Our reading of the company's report
The latest report
Thermo Fisher reported third-quarter revenue of $12.137 billion and adjusted EPS of $6.68, ahead of consensus estimates of $11.944 billion and $6.40, respectively. The supplied 10-Q excerpt does not provide the current…
Read full summary
Thermo Fisher reported third-quarter revenue of $12.137 billion and adjusted EPS of $6.68, ahead of consensus estimates of $11.944 billion and $6.40, respectively. The supplied 10-Q excerpt does not provide the current quarter’s gross margin, operating margin, free cash flow, segment results, balance-sheet detail, or quantitative guidance, limiting a full trend assessment. Controls were effective, but the company had no share repurchases in Q3 and continues to face unquantified litigation and unchanged interest-rate and currency exposures.
Reported figures
- Earnings per share
- $6.68
What stood out
-
$1.00B remains for share repurchases
The company had $1.00 billion remaining under its $5.00 billion common-stock repurchase authorization as of September 26, 2026, providing ongoing capital-allocation flexibility.
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of the quarter ended September 26, 2026.
-
No material control changes
There were no changes during the quarter ended September 26, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
No Q3 share repurchases
The company reported no share repurchase activity during the third quarter of 2026 despite $1.00 billion remaining under the authorization, which may signal a more cautious capital-allocation posture.
-
Unquantified litigation exposure
The filing identifies various lawsuits and claims involving product liability, intellectual property, employment, and commercial matters, although no quantified exposure is provided in the supplied excerpt.
-
Interest and FX risks remain
The company states that its exposure to interest-rate and currency-exchange-rate risk had not changed materially from the December 31, 2025 10-K, so these exposures remain applicable without an updated quantified sensitivity analysis.
Management's outlook
No numeric outlook was provided in the supplied 10-Q excerpt. The filing does not include updated revenue or EPS guidance; outlook may have been addressed separately in the earnings call.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.